Evelo Biosciences Inc (EVLO)

$ 9.54
0.11 (+1.17%)
-
Symbol EVLO
Price $ 9.54
Beta 1.250
Volume Avg. 0.24M
Market Cap 0.51B
Shares () -
52 Week Range 3.55-19.928
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -118.76% Strong Sell
ROA -46.17% Strong Sell
Operating Margin -
Debt / Equity 74.23% Buy
P/E -
P/B 5.07 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Evelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call Transcript

Evelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call Transcript

Evelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call Transcript ...

Seeking Alpha
Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference

Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present a company overview at t... ...

GlobeNewsWire
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People

Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commerci...

-- Collaboration expected to accelerate access to Evelo's lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select developing markets and is Abdul Latif Jameel He... ...

GlobeNewsWire
Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2020 Results - Earnings Call Transcript

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2020 Results - Earnings Call Transcript

Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2020 Results - Earnings Call Transcript ...

Seeking Alpha
Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlig...

–Announced new positive data in human experimental model of inflammation of EDP1815––Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021––Initiated Phase 1b clinical tria... ...

GlobeNewsWire
Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021

Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9,...

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast... ...

GlobeNewsWire
4D Pharma: Impressive Immuno-Oncology Data

4D Pharma: Impressive Immuno-Oncology Data

4D Pharma: Impressive Immuno-Oncology Data ...

Seeking Alpha
Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More

Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently. ...

Benzinga
Evelo Biosciences Announces Pricing of Public Offering of Common Stock

Evelo Biosciences Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the pricing of an underwritten publi... ...

GlobeNewsWire
Evelo Biosciences Announces Proposed Public Offering of Common Stock

Evelo Biosciences Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) (“Evelo”), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it intends to offer and sell, s... ...

GlobeNewsWire

About


Dr. Balkrishan Gill
Healthcare
Biotechnology
Nasdaq Global Select

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The company is headquartered in Cambridge, Massachusetts and currently employs 75 full-time employees. The firm develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases, such as colorectal cancer, renal cell carcinoma, and melanoma among others.